Abstract P1-11-09: Predictive Response Factors (PRF) in an Open, Non-Randomized, Phase II Study of a Combination of Bevacizumab (BZ) and Sequential Chemotherapy as Preoperative Treatment in Patients with Operable HER-2 Negative Breast Cancer (BC) | Publicación